[Use of disease-modifying therapies in spinal muscular atrophy 5q in Mexico]. [PDF]
Meza-Cano ME, Molina-Castillo C.
europepmc +1 more source
Pain in Children and Adolescents with Spinal Muscular Atrophy: A Longitudinal Study from a Patient Registry. [PDF]
Pitarch-Castellano I +8 more
europepmc +1 more source
Atrofia muscular espinal tipo II: un caso atípico.
Spinal Muscular Atrophy (SMA) is a recessive genetic disease that produces a degeneration and loss of the motor neurons, which turn into a denervation and muscle weakness. This happens because of a mutation or a deletion of the SMN1 and SMN2 genes, which result in the exon 7 of the RNA.
Díaz Álvarez, Efrén +1 more
openaire +1 more source
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies. [PDF]
Alves BKAMF +3 more
europepmc +1 more source
Why should a 5q spinal muscular atrophy neonatal screening program be started? [PDF]
Becker MM +5 more
europepmc +1 more source
Reabilitação em cães com atrofia muscular induzida
Pós-graduação em Cirurgia Veterinária ...
openaire +1 more source
The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease. [PDF]
Zanoteli E.
europepmc +1 more source
Cerebral and cerebellar pseudoatrophy associated with valproic acid. Report of three pediatric cases. [PDF]
Ordoño-Saiz MV +10 more
europepmc +1 more source
Quality of life in patients with spinal muscular atrophy in Brazil: patient self-assessment and carer perception. [PDF]
Coelho M +3 more
europepmc +1 more source
X-linked spinal and bulbar muscular atrophy (Kennedy's disease): the first case described in the Brazilian Amazon. [PDF]
Alves CN +5 more
europepmc +1 more source

